Navigation Links
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone

abolic disease disorders. With a pipeline consisting of four clinical-stage product candidates, Manhattan Pharmaceuticals is developing potential therapeutics for large, underserved patient populations seeking superior treatments for conditions including psoriasis, atopic dermatitis (eczema), mastocytosis, and head lice. Please visit our new corporate website at http://www.manhattanpharma.com for more information.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Manhattan Pharmaceutical's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," "will," and similar words or phrases. These statements are based on Manhattan Pharmaceuticals' current expectations, forecasts and assumptions, which are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that Manhattan Pharmaceuticals' development efforts relating to its PTH (1-34), Altoderm(TM), Altolyn(TM) or Hedrin(TM) product candidates, or any future product candidates, will be successful, or that Manhattan Pharmaceuticals will be able to out-license its discontinued programs to other companies on terms acceptable to Manhattan Pharmaceuticals, or at all. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Manhattan Pharmaceuticals' product candidates, the risk that the results of clinical trials may not support th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
4. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
5. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:3/26/2015)... LAKES, N.J. , March 26, 2015  Becton, ... today that it will commence offers to exchange all ... issued by CareFusion Corporation, a wholly owned subsidiary of ... described in the table below. A Registration Statement on ... of the New Notes was filed with the Securities ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... 2015  Imagine a loved relative suffering from cancer ... the drugs are too expensive. The Austrian Centre of ... to reduce production costs of highly valued drugs significantly. ... the mercy of pathogens or cancer cells. Therapeutic antibodies ... for controlling autoimmune diseases such as multiple sclerosis. According ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2World's First Method for Continuous Purification of Valuable Antibodies 2
... Alternatives International, Inc. ("NAI") (NASDAQ: NAII ), ... supplements, announced today that on February 6 it filed ... Inc. in U.S. District Court for the District of ... 8,067,381 ("the ,381 patent"), entitled "Methods and compositions for ...
... Feb. 14, 2012  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... call and live webcast on Monday, February 27, 2011 at ... will provide a business update and review fourth quarter and ... and press release may be accessed from the Investors section ...
Cached Medicine Technology:Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 2Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. 3
(Date:3/26/2015)... New York, NY (PRWEB) March 26, 2015 ... year to raise awareness of Parkinson’s disease and funds ... (APDA) purpose to Ease the Burden – Find the ... for registration and will take place in more than ... Phoenix, Rhode Island, New Jersey, San Antonio, Minnesota, Seattle, ...
(Date:3/26/2015)... 2015 In preparation for the 2016 ... founded by Samir Becic, has issued “report cards” ... health and fitness, as well as their promotion of ... includes Sen. Ted Cruz, who has officially announced his ... other politicians who have shown interest in running for ...
(Date:3/26/2015)... CT (PRWEB) March 26, 2015 CRN ... State Capitol Building to help celebrate the achievement of ... groundbreaking employment program serving some 500 people. , The ... The WorkPlace in partnership with the Connecticut ... and prepare long-term unemployed workers and place them at ...
(Date:3/26/2015)... Los Lunas, N.M., resident Lyndsi Alderete never ... year, when she attended a pageant and had an ... a debilitating disease of the lungs that affects the ... failure. The disease turned the Alderete’s world upside down ... pageant to raise awareness about her daughter’s disease. ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
Breaking Medicine News(10 mins):Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2Health News:Albuquerque Area Mom Enters Mrs. New Mexico Pageant to Help Fight Pulmonary Hypertension 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3
... Point Action Plan on infectious waste control during a ... Monday,s Washington Times (link below), Emergency Preparedness ... issues, such as SARS, have highlighted the vulnerability our ... the area of operational sustainability in a crisis. ...
... Increase in Free Water ClearanceTOKYO and PRINCETON, N.J., ... and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) ... Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the ... of patients with clinically significant hypervolemic and euvolemic ...
... Experiences of Denton Regional ... DALLAS, May 21 T-System, Inc., the leading provider of ... care centers, today announced that its Emergency Department Information System ... entitled "ED Information Systems: A Guideline For Successful Implementation" in ...
... the region,s most prominent business organization, today applauded Governor ... report in Atlanta, Georgia. Greater Baltimore Committee President ... process has been of great value to the bioscience ... appreciated by the business community. He is the ...
... 17 states have won awards in the "Fight the Bite" ... Prevention and the DEET Education Program. Started in 2007, ... that encourage children and adults to protect against mosquito and ... of the winning posters are at www.fightthebitecontest.org ...
... May 21 For the second year in a row, ... donate blood through the Red Cross by joining Red ... Cross Racing is a program designed to increase the ... donate. Participants of this program can get points for a ...
Cached Medicine News:Health News:Coalition Calls on Secretary of Health to Make Hospital Emergency Preparedness a Priority 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 2Health News:The T SystemEV(R) Featured in Journal of Emergency Nursing Paper on Successful EDIS Implementation 3Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 2Health News:'Fight the Bite' Poster Contest Honors 28 Students in 17 States 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: